Prognostic Relevance of Uncommon Ovarian Histology in Women With Stage III/IV Epithelial Ovarian Cancer

被引:231
作者
Mackay, Helen J. [1 ]
Brady, Mark F. [2 ]
Oza, Amit M. [1 ]
Reuss, Alexander [3 ]
Pujade-Lauraine, Eric [4 ]
Swart, Ann M. [5 ]
Siddiqui, Nadeem [6 ]
Colombo, Nicoletta [7 ]
Bookman, Michael A. [2 ]
Pfisterer, Jacobus [3 ]
du Bois, Andreas [3 ]
机构
[1] NCIC, CTG, Kingston, ON, Canada
[2] Gynecol Oncol Grp, Philadelphia, PA USA
[3] AGO OVAR, Arbeitsgemeinsch Gynaekol Onkol Studiengrp Ovaria, Wiesbaden, Germany
[4] Univ Paris 05, AP HP, Hop Hotel Dieu, Paris, France
[5] MRC, London, England
[6] Scottish Gynaecol Canc Trials Grp, Glasgow, Lanark, Scotland
[7] Ist Europeo Oncol, Milan, Italy
基金
英国医学研究理事会;
关键词
Epithelial ovarian cancer; Meta-analysis; Rare histologies; Prognosis; 1ST-LINE TREATMENT; INTERGROUP TRIAL; CARBOPLATIN; PACLITAXEL; TUMORS;
D O I
10.1111/IGC.0b013e3181dd0110
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The prognostic relevance of uncommon epithelial ovarian cancer (EOC) histological subtypes remains controversial. The Gynecologic Cancer InterGroup (GCIG) initiated this meta-analysis to assess the relative prognosis of women with a diagnosis of rare EOC histologies from completed, prospectively randomized studies performed by cooperative GCIG study groups. Methods: Studies eligible for analysis included first-line treatment of at least 150 patients with stage III/IV EOC treated with a platinum/taxane-based regimen. Collaborating groups were to provide patient-level data. Serous acted as the reference histology, and a proportional hazards model was used to estimate the relative rate of progression or death. Results: Data on 8704 women with stage III/IV EOC from 7 randomized trials were included in these analyses. Two hundred twenty-one patients (2.5%) had clear cell carcinoma; 264 (3.0%), mucinous; and 36 (0.4%), transitional cell. The mean age of patients with serous histology was greater than those with mucinous (4.1 years) and clear cell (2.6 years, P < 0.001). Mucinous, clear cell, and transitional cell tumors were more likely to be completely resected than serous (P < 0.05). When controlling for age and residual disease, mucinous and clear cell tumors had shorter times to progression (hazards ratio [HR], 2.1; 95% confidence interval [CI], 1.8-2.4 and HR, 1.6; 95% CI, 1.4-1.9, respectively) and death (HR, 2.7; 95% CI, 2.3-3.1 and HR, 2.2; 95% CI, 1.8-2.6, respectively) compared with serous. The median overall survival for serous, clear cell, mucinous, and endometrioid histologies were 40.8, 21.3, 14.6, and 50.9 months. Conclusions: Mucinous and clear cell carcinomas are independent predictors of poor prognosis in stage III/IV EOC. Studies targeting these rare histological subtypes are warranted and will require significant intergroup collaboration.
引用
收藏
页码:945 / 952
页数:8
相关论文
共 21 条
[1]  
[Anonymous], 2006, J CLIN ONCOL, V24, P5002
[2]   Cancer of the ovary [J].
Cannistra, SA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (24) :2519-2529
[3]  
CHAITIN BA, 1985, CANCER-AM CANCER SOC, V55, P1958, DOI 10.1002/1097-0142(19850501)55:9<1958::AID-CNCR2820550921>3.0.CO
[4]  
2-G
[5]   Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: A prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens [J].
du Bois, A ;
Weber, B ;
Rochon, J ;
Meier, W ;
Goupil, A ;
Bricht, S ;
Barats, JC ;
Kuhn, W ;
Orfeuvre, H ;
Wagner, U ;
Richter, B ;
Lueck, HJ ;
Pfisterer, J ;
Costa, S ;
Schroeder, W ;
Kimmig, R ;
Pujade-Lauraine, E .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) :1127-1135
[6]   2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004) [J].
du Bois, A ;
Quinn, M ;
Thigpen, T ;
Vermorken, J ;
Avall-Lundqvist, E ;
Bookman, M ;
Bowtell, D ;
Brady, M ;
Casado, A ;
Cervantes, A ;
Eisenhauer, E ;
Friedlaender, M ;
Fujiwara, K ;
Grenman, S ;
Guastalla, JP ;
Harper, P ;
Hogberg, T ;
Kaye, S ;
Kitchener, H ;
Kristensen, G ;
Mannel, R ;
Meier, W ;
Miller, B ;
Neijt, JP ;
Oza, A ;
Ozols, R ;
Parmar, M ;
Pecorelli, S ;
Pfisterer, J ;
Poveda, A ;
Provencher, D ;
Pujade-Lauraine, E ;
Randall, M ;
Rochon, J ;
Rustin, G ;
Sagae, S ;
Stehman, F ;
Stuart, G ;
Trimble, E ;
Vasey, P ;
Vergote, I ;
Verheijen, R ;
Wagner, U .
ANNALS OF ONCOLOGY, 2005, 16 :7-12
[7]   A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer [J].
du Bois, A ;
Lück, HJ ;
Meier, W ;
Adams, HP ;
Möbus, V ;
Costa, S ;
Bauknecht, T ;
Richter, B ;
Warm, M ;
Schröder, W ;
Olbricht, S ;
Nitz, U ;
Jackisch, C ;
Emons, G ;
Wagner, U ;
Kuhn, W ;
Pfisterer, J .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (17) :1320-1330
[8]   METASTATIC OVARIAN-TUMORS - STILL A CHALLENGE [J].
GERSELL, DJ .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1992, 97 (06) :745-747
[9]   Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma [J].
Gilks, C. Blake ;
Ionescu, Diana N. ;
Kalloger, Steve E. ;
Koebel, Martin ;
Irving, Julie ;
Clarke, Blaise ;
Santos, Jennifer ;
Le, Nhu ;
Moravan, Veronika ;
Swenerton, Kenneth .
HUMAN PATHOLOGY, 2008, 39 (08) :1239-1251
[10]   INTEROBSERVER VARIABILITY IN THE INTERPRETATION OF EPITHELIAL OVARIAN-CANCER [J].
HERNANDEZ, E ;
BHAGAVAN, BS ;
PARMLEY, TH ;
ROSENSHEIN, NB .
GYNECOLOGIC ONCOLOGY, 1984, 17 (01) :117-123